NCT03808376View on ClinicalTrials.gov

PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days

NACompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

December 27, 2018

Primary Completion Date

May 8, 2020

Study Completion Date

May 8, 2020

Conditions
Diabetes MellitusDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
Interventions
DEVICE

Continuous Glucose Monitoring System

The Eversense® 180 CGM System

Trial Locations (8)

30318

Atlanta Diabetes Care, Atlanta

78229

Clinical Trials of Texas, San Antonio

80045

Barbara Davis Center for Diabetes, Aurora

83404

Rocky mountain Diabetes Center C/O Research Department, Idaho Falls

92025

AMCR Institute Inc., Escondido

94520

John Muir Physician Network Clinical Research Center, Concord

94598

Diablo Clinical Research, Walnut Creek

98057

Rainier Clinical Research Center, Renton

All Listed Sponsors
lead

Senseonics, Inc.

INDUSTRY

NCT03808376 - PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days | Biotech Hunter | Biotech Hunter